In summary, the first screening round of the mismatch repair cohort of IMPACT supports consideration of targeted PSA screening for prostate cancer in men with MSH2 and MSH6 pathogenic variants to increase the detection of prostate tumours that are highly likely to need treatment based on national and international guidelines. Here, MSH6 is linked to prostate neoplasm.